Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 939-200-6 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Based on existing datasets and structural and chemical considerations, read-across from the Reaction mass of lithium 3-hydroxy-2,2,4-trimethylpentanoate and lithium isobutyrate and sodium 3-hydroxy-2,2,4-trimethylpentanoate and sodium isobutyrate to available repeated dose toxicity studies on isobutanol and isobutyl isobutyrate is appropriate to meet the REACH Annex VII-IX data requirements. In a sub-chronic, 90 day toxicity study using isobutanol in which rats were treated by oral gavage at 0,100,316 or 1000 mg/kg bw/day, the NOAEL was determined to be 316 mg/kg bw/day based on decreased bodyweight gain and transient hypoactivity and ataxia at the higher dose. The sub-chronic oral toxicity of isobutyl isobutyrate was determined to be low: the NOAEL was 1000 mg/kg bw/day (i.e. the highest dose tested).
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 30 July - 6 November 1985
- Reliability:
- 2 (reliable with restrictions)
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- Principles of method if other than guideline:
- Groups of male and female rats were dosed orally once daily with 0, 100, 316, or 1000 mg/kg/day of the compound until the day of necropsy at an interim or final sacrifice (days 29 and 30 or days 92 and 93 respectively). The first 10 male and 10 female rats from each group were scheduled for the interim necropsy and all remaining rats were sacrificed on day 92 or 93.
Body weights, food consumption, mortality, any overt signs of toxicity and ophthalmologic examinations were carried out on all animals. Blood and urine were collected from a fifth group of 10 rats/sex prior to initiation of dosing, from all surviving rats at the interim sacrifice and from 10 rats/sex/group at the final sacrifice for clinicopathologic evaluation.
Gross postmortem examinations were done on all rats and organ weights were obtained at the interim and final sacrifices. A histopathologic examination was done on all rats in the control and high-dose groups, on rats found dead or sacrificed moribund, on the livers, hearts, and kidneys of low- and mid-dose rats, and on all gross lesions. - GLP compliance:
- not specified
- Limit test:
- no
- Species:
- rat
- Strain:
- not specified
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Breeding Laboratories
- Age at study initiation: 22-23 days
- Weight at study initiation: 45-55 grams
- Fasting period before study: no
- Housing: individually in wire-botton cages
- Diet (e.g. ad libitum): Purina Certified Rodent Laboratory Chow No. 5002 (pellet) ad libitum
- Water (e.g. ad libitum): Filtered municipal water ad libitum
- Acclimation period: at least 7 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 72° F ±2 (22 ±1 °C )
- Humidity (%): 43% ± 5
- Air changes (per hr): Not reported
- Photoperiod (hrs dark / hrs light): A 12 hour light: 12 hour dark cycle
IN-LIFE DATES: From: Not reported To: Not reported - Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS: Fresh solutions of the compound (in deionized water) were prepared weekly and dosed orally at a volume of 10 ml/kg
VEHICLE
- Justification for use and choice of vehicle (if other than water): Not applicable
- Concentration in vehicle: Not reported
- Amount of vehicle (if gavage): 10 ml/kg
- Lot/batch no. (if required): Not applicable
- Purity: Not applicable - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Laboratory analyses done by the County of Muskegon, Wastewater Management System
- Duration of treatment / exposure:
- 29 and 30 days for rats subject to interim necropsy
92 and 93 for the remaining rats subject to final necropsy - Frequency of treatment:
- Daily
- Remarks:
- Doses / Concentrations:
100, 316, or 1000 mg/kg/day
Basis:
actual ingested - No. of animals per sex per dose:
- Four groups 30 rats/sex/group and a fifth group of 10/sex
- Control animals:
- yes, concurrent no treatment
- yes, concurrent vehicle
- Details on study design:
- The rats were assigned randomly to groups.
No further data on dose selection rationale reported. - Positive control:
- Not applicable
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: at least twice daily 7 days a week
- Cage side observations: mortality and clinical effects
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: at least twice daily 7 days a week
BODY WEIGHT: Yes
- Time schedule for examinations: weekly
FOOD CONSUMPTION:
- Food consumption for each animal determined: Yes
- Time schedule for examinations: weekly
FOOD EFFICIENCY: No
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): Not applicable
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: during the pretreatment period and week 13
- Dose groups that were examined: All rats
HAEMATOLOGY: Yes
- Time schedule for collection of blood: prior to initiation of dosing from group V, during week 4 or 5 from interim sacrifice rats, during week 13 or 14 from final sacrifice rats
- Anaesthetic used for blood collection: Yes (CO2)
- Animals fasted: No
- How many animals: 10 male and 10 female rats in group V, all surviving rats scheduled for the interim, and the first 10 (numerically) surviving males and first ten surviving females from each group at the final sacrifice
- Parameters checked: haemoglobin, hematocrit, erythrocyte count, mean cell volume, mean cell haemoglobin, mean cell haemoglobin concentration, total and differential leucocyte counts, estimated platelet count
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: prior to initiation of dosing from group V, during week 4 or 5 from interim sacrifice rats, during week 13 or 14 from final sacrifice rats
- Animals fasted: No
- How many animals: 10 male and 10 female rats in group V, all surviving rats scheduled for the interim, and the first 10 (numerically) surviving males and first ten surviving females from each group at the final sacrifice
- Parameters checked: alkaline phosphatase, blood urea nitrogen, glutamate pyruvate transaminase, glutamate oxaloacetate transaminase, glucose,
total protein, albumin, A/G ratio (calculated), globulin (calculated), total bilirubin, sodium, potassium, chloride, calcium, creatinine, inorganic phosphate, total carbon dioxide, total serum cholesterol.
URINALYSIS: Yes
- Time schedule for collection of urine: prior to initiation of dosing from group V, during week 4 or 5 from interim sacrifice rats, during week 13 or 14 from final sacrifice rats
- Metabolism cages used for collection of urine: Yes
- Animals fasted: No
- Parameters checked: pH, specific gravity, glucose, protein, bilirubin, ketones, urobilinogen, microscopy of sediment.
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes (see table 1)
A necropsy was performed on the surviving rats of the first 10 males and 10 females from each dose group on day 29 or 30 of the study. On days 92 or 93 the remaining rats were sacrificed. Rats found dead were necropsied immediately after they were found.
At the interim and final sacrifices, rats were anesthetized with CO2 and exsanguinated by cardiac puncture. The cranial, thoracic and peritoneal cavities were opened and the contents examined macroscopically. The organs and tissues listed in table 1 were removed from each animal and preserved.
Lungs of rats at the scheduled sacrifice were inflated with formalin via the trachea. Eyes with attached optic nerve from all rats killed at the interim and final sacrifices were preserved in a modified Zenker's fixative. The testes with attached epididymides of all male rats were preserved in Bouin's fixative. All other tlssues were preserved in 10% neutral-buffered formalin. Feet were preserved with the tissues for positive identification of the rat.
At the interima and final sacrifices, the following organs were weighed: brain, heart, liver, spleen, kidneys, testes with epididymides, and ovaries. Adrenals and thyroids with parathyroids were weighed at the final sacrifice. For paired organs, the organ weight was the combined weight of right and left members of the pair. Organ/ body weight ratios were determined for each tissue. No organ weights were taken on rats found dead.
HISTOPATHOLOGY: Yes (see table 1)
The full tissue microscopic examination listed in table 1 was done on the control and high-dose rats and on those dying on study or sacrificed in extremis. Also livers, hearts, and kidneys of low- and mid-dose rats, and all gross lesions seen at necropsy were examined microscopically. - Other examinations:
- No further data
- Statistics:
- The body weight, food consumption, clinicopathologic, and organ weight data were tested for homogeneity of variance by Bartlett's method. If the data were found to be homogeneous, differences between control and treatment means were tested for statistical significance by the method of Dunnett. If the data were found not to be homogeneous, the method of Gill (modified Dunnett's) was employed.
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Treatment related clinical signs were restricted to the high-dose group and included hypoactivity ataxia and salivation.
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- Treatment related clinical signs were restricted to the high-dose group and included hypoactivity ataxia and salivation.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- During week 1 the males of the high-dose group gained 18% less than the controls.
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- For the first 2 weeks of the study, food consumption averages of the high-dose group, males and females were significantly lower than controls.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- CLINICAL SIGNS AND MORTALITY
Treatment related clinical signs were restricted to the high-dose group and included hypoactivity ataxia and salivation.
BODY WEIGHT AND WEIGHT GAIN
During week 1 the males of the high-dose group gained 18% less than the controls.
FOOD CONSUMPTION
For the first 2 weeks of the study, food consumption averages of the high-dose group, males and females were significantly lower than controls.
OPHTHALMOSCOPIC EXAMINATION
No test compound related effects.
HAEMATOLOGY
No test compound related effects.
CLINICAL CHEMISTRY
No test compound related effects.
URINALYSIS
No test compound related effects.
ORGAN WEIGHTS
No test compound related effects.
GROSS PATHOLOGY
No test compound related effects.
HISTOPATHOLOGY: NON-NEOPLASTIC
No test compound related effects.
HISTOPATHOLOGY: NEOPLASTIC (if applicable)
No test compound related effects. - Dose descriptor:
- NOAEL
- Effect level:
- ca. 316 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: clinical signs; body weight; food consumption
- Critical effects observed:
- not specified
- Conclusions:
- Oral administration of isobutyl alcohol produced treatment related effects at the highest dose level of 1000 mg/ kg/ day, but not at dose levels of 100 or 316 mg/kg/day. Therefore the NOAEL is considered to be 316 mg/kg/day.
- Executive summary:
- Groups of male and female rats were dosed orally once daily with 0, 100,
316, or 1000 mg/kg/day of the compound until the day of necropsy at an
interim or final sacrifice (days 29 and 30 or days 92 and 93
respectively). The first 10 male and 10 female rats from each group were
scheduled for the interim necropsy and all remaining rats were sacrificed
on day 92 or 93.
Body weights, food consumption, mortality, any overt signs of toxicity and ophthalmologic examinations were carried out on all animals. Blood and urine were collected from a fifth group of 10 rats/sex prior to initiation of dosing, from all surviving rats at the interim sacrifice and from 10 rats/sex/group at the final sacrifice for clinicopathologic evaluation.
Gross postmortem examinations were done on all rats and organ weights were obtained at the interim and final sacrifices. A histopathologic examination was done on all rats in the control and high-dose groups, on rats found dead or sacrificed moribund, on the livers, hearts, and kidneys of low- and mid-dose rats, and on all gross lesions.
Isobutyl alcohol produced definite treatment-related effects at a dose level of 1000 mg/kg/day, but not at 100 or 316 mg/kg/day. The most pronounced clinical effect was hypoactivity, which was observed during week 1 in every rat at the 1000 mg/kg/day dose level. The incidence of hypoactivity decreased markedly after week 4. During week 1, the body weight gain of the 1000 mg/kg/day males was slightly (18%) lower than that of the control s. Food consumption averages for males and females at this dose level were below control averages for weeks 1 and 2. Serum potassium levels in the 1000 mg/kg/day males and females were 11-15% below the controls of the interim evaluation but similar to controls at the final evaluation.
No effect related directly to treatment was observed in organ weight averages, at the opthalmoscopic examination or at the gross and microscopic tissue examinations. Several rats died during the study, but gross and microscopic evaluation indicated that these deaths were due either to oesophageal perforation or to tracheal inflammation (and/or necrosis) probably resulting from aspiration of isobutyl alcohol and/or its vapours.
In conclusion, the NOAEL was considered to be 316 mg/kg/day.
Reference
Lesions were seen in the tissues from the thoracic cavity of all 15 rats which were found dead but gross and microscopic evaluation indicated that these deaths were due either to oesophageal perforation or to tracheal inflammation (and/or necrosis) probably resulting from aspiration of isobutyl alcohol and/or its vapours.
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 316 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- Klimisch score = 1. The key study is an acceptable, well documented 90-day repeated dose study which meets scientific principles and is therefore reliable for the determination of the sub-chronic endpoint.
Repeated dose toxicity: inhalation - systemic effects
Link to relevant study records
- Endpoint:
- repeated dose toxicity: inhalation
- Data waiving:
- other justification
- Justification for data waiving:
- other:
- Critical effects observed:
- not specified
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Link to relevant study records
- Endpoint:
- repeated dose toxicity: inhalation
- Data waiving:
- other justification
- Justification for data waiving:
- other:
- Critical effects observed:
- not specified
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Link to relevant study records
- Endpoint:
- repeated dose toxicity: dermal
- Data waiving:
- other justification
- Justification for data waiving:
- other:
- Critical effects observed:
- not specified
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Link to relevant study records
- Endpoint:
- repeated dose toxicity: dermal
- Data waiving:
- other justification
- Justification for data waiving:
- other:
- Critical effects observed:
- not specified
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
No studies on the repeated oral dose toxicity of the Reaction mass of lithium 3-hydroxy-2,2,4-trimethylpentanoate and lithium isobutyrate and sodium 3-hydroxy-2,2,4-trimethylpentanoate and sodium isobutyrate are available. Read-across from the substance to repeated dose toxicity studies on isobutanol and isobutyl isobutyrate is appropriate to meet the REACH Annex VII-IX data requirements.Read-across is scientifically justified and also enables the REACH requirements to be adequately addressed, while avoiding unnecessary animal testing in accordance with EU Directive 86/609/EEC.
The subchronic repeated oral dose toxicity of isobutanol was investigated in rats in a 90-day oral gavage study (Toxicology Research Laboratories, 1987). In the study, groups of thirty male and female CD rats received isobutanol via oral intubation at dose levels of 0, 100, 316, or 1000 mg/kg bw/day for 90 days. Clinical signs related to treatment at the 1000 mg/kg dose level included hypoactivity, ataxia, and salivation. Clinical signs of hypoactivity and ataxia were resolved by the 4th week of the study. Slight decreases in food consumption and body weight gains were noted in the first two weeks and were restricted to the 1000 mg/kg/day group. There were no changes in organ weights or gross or histopathology at any exposure level. The NOAEL for repeated-dose toxicity was considered to be 316 mg/kg bw/day.
The repeated dose oral toxicity of isobutyl isobutyrate in rats was investigated in an 18-week subchronic oral gavage toxicity study, considered to have a reliability score of 2 (Drakeet al., 1978). In the study, Wistar rats (15/sex/dose level) were dosed at levels of 0, 10, 100, or 1,000 mg/kg bw/day for 7 days/week. Control animals received corn oil alone at 5 ml/kg. In addition, groups of five rats of each sex were given the same doses for either 2 weeks or 6 weeks. The animals were weighed on Day 1, 2, 6 and weekly thereafter. After the final dose, the animals were fasted for 24 hours and killed under barbiturate anesthesia.
Examination of blood and urine and the weights and microscopic structure of a limited range of organs were conducted. Hematology parameters were collected at 3, 6, and 18 weeks into the study. A gross necropsy was performed and brain, heart, liver, spleen, kidney, adrenals, stomach, small intestine, caecum, gonads, pituitary, and thyroid(s) were weighed. Typical organs were collected, fixed in formalin, and processed for histological examination. Urine was collected during weeks 2, 6, and 18 of treatment and examined. Kidney function tests were also performed during weeks 6 and 18.
No deaths or abnormal behaviour was observed in the study. No differences in body weight, food or water consumption or histological findings were noted. The only change in haematological parameters observed was a decrease in hemoglobin in males at 100 and 1000 mg/kg bw/day after two weeks of exposure. These changes were not accompanied by changes in other red blood cell parameters in these groups, and the female animals were not affected. In addition, similar findings were not observed at the 6 and 18-week haematology determinations. At 1000 mg/kg bw/day, there was an increase (14%) in relative spleen weight that coincided with a decrease in relative body weights in males which was not considered significant. The mean terminal body weights of animals in this group were decreased by 7% compared to the control group (not statistically significant but may explain the increased relative spleen weight). Due to the fact that there were no histological changes in this or any other organ, this finding was considered spurious.
Based on these findings, the NOAEL for the subchronic, repeated dose toxicity of isobutyl isobutyrate was determined to be 1000 mg/kg bw/day, i.e. the highest dose tested.
Justification for selection of repeated dose toxicity via oral route - systemic effects endpoint:
Based on existing datasets and structural and chemical considerations, read-across from the Reaction mass of lithium 3-hydroxy-2,2,4-trimethylpentanoate and lithium isobutyrate and sodium 3-hydroxy-2,2,4-trimethylpentanoate and sodium isobutyrate to available repeated dose toxicity studies on isobutanol and isobutyl isobutyrate is appropriate to meet the REACH Annex VII-IX data requirements. In a sub-chronic toxicity study using isobutanol in rats, the NOAEL was determined to be 316 mg/kg bw/day based on decreased bodyweight gain and transient hypoactivity and ataxia at the higher dose.
Justification for classification or non-classification
Based on read-across to available data on isobutyl isobutyrate and isobutanol, the Reaction mass of lithium 3-hydroxy-2,2,4-trimethylpentanoate and lithium isobutyrate and sodium 3-hydroxy-2,2,4-trimethylpentanoate and sodium isobutyrate is not predicted to cause any effects that meet the criteria for classification for systemic or target organ toxicity after repeated exposures.On this basis, the substance does not meet the criteria for classification for repeated dose toxicity according to Directive 67/548/EEC or Regulation 1272/2008/EC.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.